Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aspen Aerogels Inc (ASPN) vs Cytokinetics Inc (CYTK) Price & Performance

Aspen Aerogels IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Aspen Aerogels Inc vs Cytokinetics Inc — how do they compare? Aspen Aerogels Inc trades at $6.14 (market cap $509.55M), while Cytokinetics Inc trades at $76.67 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 20.9× Aspen Aerogels Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.

ASPNCYTK
Market Cap
$509.55M$10.63B
Sector
TechnologyTechnology
52-Week High
$8.82$87.26
52-Week Low
$2.57$34.31
Enterprise Value
$482.96M$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aspen Aerogels Inc

ASPN trades at $6.14, down 2.38% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $389.55 million in 2025, though Q2 2026 revenue beat estimates and Q3 guidance suggests recovery. Analyst consensus is strongly bullish with 82.61% buy ratings.

Outlook hinges on execution of revenue growth and margin improvement, particularly in thermal barrier segments. Risks include persistent negative profitability, high cash burn, and competitive pressures in EV materials. The stock offers speculative upside if operational targets are met.

Cytokinetics Inc

CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.

The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK